Transcription of Some stats - ACP
{{id}} {{{paragraph}}}
11/7/2015 1 Submassive PE -- What s new in 2015? W. Graham Carlos MD, MSCR 11/6/2015 Disclosures Industry: None Disclosures Industry: None Practically: I am giving this talk on <24 hours notice Disclosures Industry: None Practically: I am giving this talk on <24 hours notice Emotionally: I am thrilled to be a part of the meeting! Objectives Define Submassive PE Predict which patients with PE will have poor outcomes and identify what those outcomes are Identify the risks and benefits of TPA treatment for submassive PE Recognize the emerging role of catheter directed thrombolysis for treatment of submassive PE MASSIVE ~5% of PEs 58% 90-day mortality SUBMASSIVE ~40% of PEs 22% 90-day mortality LOW RISK ~55% of PEs <1% 90-day mortality Som
Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from …
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}
Size, function, and pulmonary hypertension, Pulmonary HTN, ECHO, Cardiovascular Pathophysiology : Left To Right, Pulmonary, Tricuspid and Pulmonic Valve Disease, Physiology Respiration Doppler Veins, Echo in Pulmonary HTN, In Pulmonary, Hypertension, HTN PULMONARY, EVALUATION OF VALVULAR, A Clinical and Coding Perspective, HCPro, Diagnostic Cardiology Procedures and Medical Necessity